Exclusive Agreement Sample Contracts

Smartheat Inc. – Exclusive Agreement (July 12th, 2019)

Based upon good trust, in consideration of the long-term development strategy of both parties, the following agreement has been reached after friendly negotiation between the two parties.

BlackRock Inc. – $65 billion of quarterly total net inflows, or 4% organic asset growth, positive across index, active and cash management strategies 5% decrease in base fees year-over-year primarily reflects impact of negative markets in the fourth quarter and continued dollar appreciation 11% growth in technology services revenue year-over-year, driven by continued momentum in Aladdin® 1% decrease in diluted EPS year-over-year reflects lower operating income and a higher effective tax rate in the current quarter, partially offset by higher nonoperating income $1.6 billion of share repurchases in the quarter (April 16th, 2019)
Heidrick & Struggles International Inc – Heidrick & Struggles Enters into Exclusive Agreement with Business Talent Group to Offer High-Impact, On-Demand Executive Talent Solutions (January 15th, 2019)

CHICAGO and LOS ANGELES, Jan. 15, 2019 – Heidrick & Struggles (Nasdaq: HSII), the premier provider of executive search, leadership assessment and development, organization and team effectiveness, and culture shaping services globally, today announced an exclusive collaboration with Business Talent Group (BTG), the leading high-end marketplace for on-demand independent talent. With this agreement, Heidrick & Struggles will offer its clients seamless access to BTG’s pool of top independent business professionals – on demand – for critical, project-based assignments.

Youngevity International, Inc. – EXCLUSIVE AGREEMENT BETWEEN ICELANDIC WATER HOLDINGS HF. AND YOUNGEVITY INTERNATIONAL, INC. Date: 01/10/19 (January 11th, 2019)

Icelandic Water Holdings hf., an Icelandic public limited company with its registered office at Hl’ðarendi, 816 Ölfus, Iceland, and registered under registration number 650997-2129 (“IWH”).

Zomedica Pharmaceuticals Corp. – Zomedica Signs Exclusive Agreement with Qorvo Biotechnologies for Global Veterinary Rights to Diagnostic Point-of-Care Platform Sensor-based technology aims to provide veterinarians with collection of rapid reference-lab quality tests at the point-of-care (November 28th, 2018)

ANN ARBOR, Mich., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM), a veterinary diagnostic and pharmaceutical company, today announced it has entered into a development and supply agreement with Qorvo Biotechnologies, LLC (Qorvo), a wholly-owned subsidiary of Qorvo, Inc. (Nasdaq: QRVO) focused on bringing its piezo-electric Bulk Acoustic Wave (BAW) sensor to the veterinary health sector. Under the terms of this agreement, Zomedica has exclusive, global rights to develop and market Qorvo’s investigational point-of-care diagnostic platform for veterinary use.

Sutro Biopharma Inc – AMENDED AND RESTATED EXCLUSIVE AGREEMENT (September 17th, 2018)

This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Fundamental Applied Biology, Inc. (“FAB”), a corporation having a principal place of business at 1455 Adams Drive, Bldg. 15, Suite 1015, Menlo Park, CA 94025, is effective on the 3 day of October, 2007 (“Effective Date”).

Riot Blockchain, Inc. – RiotX Enters Exclusive Agreement with Coinsquare in Anticipation of Launching a U.S. Focused Cryptocurrency Exchange (September 7th, 2018)

FORT LAUDERDALE, FL, September 4, 2018 /Accesswire/ -- Riot Blockchain, Inc. (NASDAQ: RIOT) (“the Company”) announced that its subsidiary RiotX Holdings Inc (“RiotX”) has entered into a Software License and Services Agreement (the “Agreement”) with goNumerical Ltd. (dba “Coinsquare”) to provide a RiotX branded version of the Coinsquare platform with customized functional integrations and associated transaction processing services for use by RiotX.  RiotX has obtained an exclusive license for the U.S. market through this partnership with Coinsquare.  The Company intends to provide this offering for select customers at RiotX.com.

WestRock Co – Investor Presentation August 2018 | 2 Forward Looking Statements This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , including but not limited to the statements on the slides entitled “Q3 FY18 Key Highlights”, “Full - Year 2018 Guidance”, “Long - Term Growth FY18 - FY22”, “KapStone Brings Enhanced Scale and Expanded Product Offering”, “Expected KapStone Synergies”, “Acquisition of Plymouth Packaging”, “Key Commodity Annual Consumption Volumes and FX by Currency”, and “Mill Maintenance Schedule”, that give guidance (August 13th, 2018)
Zomedica Pharmaceuticals Corp. – Zomedica Signs Agreement With Seraph Biosciences for Innovative Veterinary Point-of-Care Diagnostic Exclusive agreement intended to bring human medical diagnostic technology to the veterinary practice workflow (May 10th, 2018)

ANN ARBOR, Mich., May 10, 2018 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (TSX-V:ZOM), a veterinary diagnostic and pharmaceutical company, today announced it has entered into a development, commercialization and exclusive distribution agreement with Seraph Biosciences, Inc. (“Seraph”), a human biomedical device company. Under the terms of this agreement, Zomedica will have exclusive global veterinary industry rights to develop and market a novel pathogen detection system in the form of an innovative point-of-care diagnostic instrument.

WestRock Co – Investor Presentation May 2018 | 2 Forward Looking Statements This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , including but not limited to the statements on the slides entitled “Q2 FY18 Key Highlights”, “Full - Year 2018 Guidance”, “Long - Term Growth FY18 - FY22”, “Acquisition of KapStone Paper & Packaging”, “KapStone Brings Enhanced Scale and Expanded Product Offering”, “Expected KapStone Synergies”, “Acquisition of Ply mouth Packaging”, “Synergy and Performance Improvements”, “Key Commodity Annual Consumpti (May 7th, 2018)
WestRock Co – Citi Investor Meetings February 2018 | 2 Forward Looking Statements OUTSTANDING EXECUTION & DELIVERY DISCIPLINED CAPITAL ALLOCATION BROAD PORTFOLIO OF DIFFERENTIATED SOLUTIONS This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , including but not limited to the statements on the slides entitled “Q1 FY18 Key Highlights”, “Full - Year 2018 Guidance”, “Long - Term Growth FY18 - FY22”, “Acquisition of KapStone Paper & Packaging”, “ KapStone Brings Enhanced Scale and Expanded Product Offering”, “Expected KapStone Synerg (February 13th, 2018)
Aar Corp – AAR 2018 Investor Day New York January 11, 2018 1 AAR Corp. All rights reserved worldwide. Confidential and proprietary document. Forward-Looking Statements This presentation includes certain statements relating to future results, which are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on beliefs of Company management, as well as assumptions and estimates based on information currently available to the Company, and are subject to certain risks and uncertainties that could cause actual resul (January 11th, 2018)
Opko Health, Inc. – OPKO Health Enters into Exclusive Agreement with Japan Tobacco to Develop and Commercialize RAYALDEE® in Japan OPKO to receive up to $118 million in upfront and milestone payments, plus tiered double-digit royalties on product sales (October 12th, 2017)

MIAMI (October 12, 2017) – OPKO Health, Inc. (NASDAQ: OPK) announced that its subsidiary EirGen Pharma has entered into an exclusive agreement with Japan Tobacco Inc. (JT) for the development and commercialization in Japan of RAYALDEE® for the treatment of secondary hyperparathyroidism (SHPT) in non-dialysis and dialysis patients with chronic kidney disease (CKD).

Abaxis Inc – THIRD AMENDMENT TO THE EXCLUSIVE AGREEMENT BETWEEN ABBOTT POINT OF CARE INC. AND ABAXIS, INC. (August 9th, 2017)

This Third Amendment (“Third Amendment”) to that certain Exclusive Agreement (“Agreement”) dated as of October 26, 2012 is effective as of July 11, 2017 (“Third Amendment Effective Date”) between Abaxis, Inc., (“ABAXIS”) and Abbott Point of Care Inc., (“ABBOTT”) relating to the appointment of ABBOTT to sell and distribute Abaxis Products. Any capitalized term used and not otherwise defined herein shall have the meaning set forth in the Agreement.

Abaxis Inc – SECOND AMENDMENT TO THE EXCLUSIVE AGREEMENT BETWEEN ABBOTT POINT OF CARE INC. AND ABAXIS, INC. (August 9th, 2017)

This Second Amendment (“Second Amendment”) to that certain Exclusive Agreement (“Agreement”) dated as of March 7, 2017, is effective as of April 19, 2017 (“Amendment Effective Date”) between Abaxis, Inc. (“ABAXIS”) and Abbott Point of Care Inc. (“ABBOTT”) relating to the appointment of ABBOTT to sell and distribute Abaxis Products. Any capitalized term used and not otherwise defined herein shall have the meaning set forth in the Agreement.

Biodelivery Sciences International Inc – BIODELIVERY SCIENCES SIGNS EXCLUSIVE AGREEMENT WITH PURDUE PHARMA (CANADA) FOR THE LICENSING AND DISTRIBUTION RIGHTS OF BELBUCA® IN CANADA (July 18th, 2017)

Raleigh, North Carolina (USA) and Pickering, Ontario (CANADA), July 12, 2017: Today, BioDelivery Sciences International Inc. (NASDAQ: BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine, and Purdue Pharma (Canada) announce that they have signed an exclusive agreement for the licensing, distribution, marketing and sale of BELBUCA® (buprenorphine buccal film) in Canada.

Nxt-Id, Inc. – Mobile Security For a Mobile World ® Gino Pereira Chief Executive, NXT - ID Inc. Certain matters discussed in this presentation and management’s statements related thereto contain forward - looking statements that involve material risks to and uncertainties in our business that may cause actual results to differ materially from those anticipated by the statements made herein . Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others (June 29th, 2017)
Chembio Diagnostics, Inc. – Chembio Expands Product Distribution through Exclusive Agreement with Isla Lab in the Caribbean (August 18th, 2016)
Terra Tech Corp. – Terra Tech's Subsidiary, Edible Garden, Signs Exclusive Agreement with Nutrasorb to Produce and Commercialize Nutrient-Rich Salad Blend Partnership to develop first-ever nutritionally-enhanced lettuce varieties at Rutgers University (April 20th, 2016)

NEWPORT BEACH, Ca. – April 14, 2016 – Terra Tech Corp. (OTCQX: TRTC) ("Terra Tech") or (the "Company"), today announced that its subsidiary, Edible Garden, a retail seller of locally grown hydroponic produce, herbs, and floral products, has signed an exclusive license agreement with Nutrasorb LLC, a spin-off of Rutgers University, to grow and commercialize nutritionally-enhanced lettuce varieties.

Second Sight Medical Products Inc – SECOND SIGHT ANNOUNCES EXCLUSIVE AGREEMENT WITH TECNOSALUD TO BRING THE ARGUS II RETINAL PROSTHESIS TO ARGENTINA (February 12th, 2016)

SYLMAR, Calif.—February 9, 2016— Second Sight Medical Products, Inc. ("Second Sight" or "the Company") (Nasdaq:EYES), a developer, manufacturer and marketer of implantable visual prosthetics to restore some useful vision to blind patients, today announced plans to expand into South America by signing an exclusive agreement with Tecnosalud to distribute the Argus® II Retinal Prosthesis System ("Argus II") in Argentina.

Celladon Corp – EXCLUSIVE AGREEMENT (December 14th, 2015)

This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Eiccose, LLC (“Eiccose”), a Delaware limited liability company having a principal place of business at 1115 Lafayette Street, Santa Clara, CA 95050, is effective on the 27th day of October 2015 (“Effective Date”).

Celladon Corp – EXCLUSIVE AGREEMENT (December 14th, 2015)

This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Eiccose, LLC (“Eiccose”), a Delaware limited liability company having a principal place of business at 1115 Lafayette Street, Santa Clara, CA 95050, is effective on the 1st day of May 2015 (“Effective Date”).

Mobiquity Technologies, Inc. – Exclusive Agreement with leading mall owner adds 35 premier retail properties to Mobiquity Networks’ nationwide mobile platform reach (December 3rd, 2015)

GARDEN CITY, N.Y., December 03, 2015 --Mobiquity Networks, a wholly owned subsidiary of Mobiquity Technologies, Inc. (OTCQB:  MOBQ), which powers a leading national location-based mobile advertising and app engagement network, has partnered with Rouse Properties, Inc. (“Rouse) (NYSE: RSE), a national owner and operator of enclosed regional malls and retail centers, to be the exclusive provider of beacon-based advertising services at all of Rouse’s properties nationwide.

Fuelstream INC – FUELSTREAM SIGNS 2-YEAR EXCLUSIVE AGREEMENT TO PROVIDE FUEL FOR SKYWISE AIRLINE IN SOUTH AFRICA (December 2nd, 2015)

DRAPER, UT, FL – (PRWeb – November 30, 2015) – Fuelstream, Inc. (OTC: FLST) (“Fuelstream” or the “Company”), a worldwide supplier of aviation fuel and flight services, announced today that it has signed an agreement with Pak Africa Trade Zone (Pty) Limited, the operator of Skywise Airline in South Africa, to be its exclusive provider of aviation fuel for a 2-year period commencing on the 25th of November 2015. Launched in March 2015, Skywise Airlines is a low-cost commercial carrier based in Johannesburg, South Africa which provides regular passenger service between Johannesburg and Cape Town.

Amag Pharmaceuticals Inc. – AMAG Pharmaceuticals 3Q 2015 Financial Results November 3, 2015 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including among others, statements regarding future growth drivers for Makena, including expectations for approval and commercialization of the single-dose (1 mL) preservative-free vial; expectations for the lifecycle management program for Makena, including the development and advantages of a subcu (November 3rd, 2015)
Second Sight Medical Products Inc – Second Sight Announces Exclusive Agreement with Gulf Medical Company to Distribute the Argus II Retinal Prosthesis System in Saudi Arabia (May 13th, 2015)

Sylmar, California- May 7, 2015 – Second Sight Medical Products, Inc. (“Second Sight” or “the Company”) (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics to restore some useful vision to blind patients, has signed an exclusive agreement with Gulf Medical Company (“Gulf Medical”), one of the largest distributors of medical products to Saudi Arabia and the Gulf region, to distribute the Argus® II Retinal Prosthesis System (“Argus II”) in Saudi Arabia with certain minimum purchase requirements.

Chembio Diagnostics, Inc. – MEDFORD, NY, October 27, 2014 – Chembio Diagnostics, Inc. (NASDAQ:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that it has entered into an exclusive agreement with Integrated BioTherapeutics, Inc. (IBT), a biotechnology company focused on the discovery of novel vaccines and therapeutics for emerging infectious diseases. Under the terms of the agreement, Chembio will combine its patented DPP® technology with IBT's proprietary Ebola reagents to develop POC diagnostic tests for Ebola and febrile illness. Chembio will have exclusive rights to any (October 28th, 2014)
Histogenics Corp – FIRST AMENDMENT TO EXCLUSIVE AGREEMENT (October 7th, 2014)

This First Amendment, effective as of October 26, 2005, by and between the Board of Trustees of the Leland Stanford Junior University, a body having corporate powers under the laws of the State of California (“Stanford”), and Histogenics Corporation, a Massachusetts corporation (“Histogenics”), serves to amend the Exclusive Agreement between Stanford and Licensee, titled “Restoration of Articular Cartilage Matrix” dated April 15, 2001 and described in Stanford docket S98-181 (the “Agreement”). Stanford and Histogenics agree as follows:

Histogenics Corp – CONFIDENTIAL TREATMENT REQUESTED SECOND AMENDMENT TO EXCLUSIVE AGREEMENT (October 7th, 2014)

This Second Amendment, effective as of January 15, 2006, by and between the Board of Trustees of the Leland Stanford Junior University, a body having corporate powers under the laws of the State of California (“Stanford”), and Histogenics Corporation, a Massachusetts corporation (“Histogenics”), serves to amend the April 15, 2001 agreement between Stanford and Licensee as follows:

Histogenics Corp – EXCLUSIVE AGREEMENT (October 7th, 2014)

Effective as of April 15, 2001 (“Effective Date”), THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, a body having corporate powers under the laws of the State of California (“STANFORD”), and Histogenics Corporation, a Massachusetts corporation having a principal place of business at 116 Pleasant Street, Suite 19, Easthampton, Massachusetts, 01027 (“LICENSEE”), agree as follows:

Rbc Life Sciences, Inc. – EXCLUSIVE AGREEMENT (August 28th, 2014)

This agreement (the “Agreement”) is made as of the 1st day of August, 2014, by and between RBC Life Sciences, Inc., a Nevada corporation with offices at 2301 Crown Court, Irving, Texas, 75038, USA, (“RBC” or “Supplier”), and Coral Club International Inc., an Ontario corporation, with offices at 255 Duncan Mill Road, Suite 806, Toronto, ON, M3B 3H9, Canada (“CCI” or “Purchaser”).

CareDx, Inc. – AMENDED AND RESTATED EXCLUSIVE AGREEMENT (July 15th, 2014)

This Amended and Restated Agreement (“Restated Agreement”) between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and ImmuMetrix, Inc. (“ImmuMetrix”), a corporation having a principal place of business at 3183 Porter Drive, Palo Alto, CA, is effective on the 27th day of January, 2014, (“Restatement Effective Date”).

CareDx, Inc. – AMENDED AND RESTATED EXCLUSIVE AGREEMENT (June 3rd, 2014)

This Amended and Restated Agreement (“Restated Agreement”) between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and ImmuMetrix, Inc. (“ImmuMetrix”), a corporation having a principal place of business at 3183 Porter Drive, Palo Alto, CA, is effective on the 27th day of January, 2014, (“Restatement Effective Date”).

Actavis Plc – Actavis Extends Exclusive Agreement to Distribute Authorized Generic Concerta® (May 20th, 2014)

DUBLIN, IRELAND – May 15, 2014 – Actavis plc (NYSE: ACT) today announced that it has reached an agreement with Janssen Pharmaceuticals, Inc. (JPI) to continue supplying the authorized generic version of JPI’s Concerta® (methylphenidate hydrochloride extended-release tablets).

Xenonics Holdings, Inc. – Xenonics Announces Exclusive Agreement with Saudi International Military Services (May 19th, 2014)

CARLSBAD, CALIFORNIA — May 15, 2014 — XENONICS HOLDINGS, INC. (OTCQB:XNNH) today announced today that it signed an exclusive international agreement with Saudi International Military Services, Ltd. (“SIMS”). This Agreement established SIMS as an international exclusive dealer of Xenonics Holdings, Inc.